A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Axitinib
DRUG: MK-3475

Sponsor

Pfizer

Collaborators

[object Object]